This report provides all the information you require to better understand CSL and its partnering interests and activities over the past seven years.

CSL is a top pharmaceutical company based in Melbourne, Australia

CSL is a large speciality biopharmaceutical company developing and manufacturing plasma products and vaccines to treat and protect patients worldwide.

CSL has announced only 1 M&A deal since 2005, with the acquisition of Zenyth Therapeutics

CSL is a global pharma company active in the development of vaccines and plasma proteins with a prime focus on influenza vaccine – partnering, collaborative R&D and licensing activity of CSL is reviewed here.

CSL, a top pharmaceutical company, is reviewed in terms of partnering, licensing and M&A interests and activity over recent years

This month we provide you with an overview of deal analysis in the life science sectors, covering partnering, M&A and financing in October 2014.

This month we provide you with an overview of deal analysis in the life science sectors, covering partnering, M&A and financing in December 2013

Dealtalk: Plans to develop Xenome’s molecule, derived from shellfish venom, to soothe acute post-surgery pain, have been shipwrecked.

Partnering activity of the biopharma companies in Forbes Most Innovative Company list reviewed

It is a rare event to see a multi-billion dollar acquisition take place involving a company outside the bigpharma top 50.

Novartis announced has entered an agreement that CSL has acquired its influenza vaccine business in a $275 million deal that will require regulatory approval before it closes by the end of the second half of 2015.

Vaccine maker and blood products specialist CSL in $950m share buyback.

A popular headlines on the pharma news was CSL Biotherapies award of $1.5billion from the United States Department of Health and Human Services to supply pre-pandemic and pandemic vaccine antigens and related services to the U.S. national stockpile .

The six-year agreement with CSL Biotherapies, a division of CSL, calls for Merck to market Afluria in the United States, where it was approved by the Food and Drug Administration in 2007, starting next year. CSL will make the vaccine and maintain marketing and distribution rights in the rest of the world.

Merck will assume responsibility for all aspects of commercialization of AFLURIA in the U.S. CSL will supply AFLURIA to Merck and will retain responsibility for marketing the vaccine outside the U.S. Specific financial details of the agreement were not disclosed.

Castlight Health is to raise $176 million in IPO financing.